Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
February 25, 2021 07:03 ET
|
Altimmune, Inc.
Nasal spray may offer room temperature distribution that could reduce logistical challenges for healthcare systems and providers Intranasal administration targets the virus at its point of entry and...